ArticleEpilepsia2022
Multicenter, cross-sectional study of the costs of illness and cost-driving factors in adult patients with epilepsy.
Article in Epilepsia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- A multicenter randomized controlled feasibility trial of a digital self-management intervention for adults with epilepsy.Epilepsia open · 2024Trial
- Effectiveness and safety of cenobamate after conversion to monotherapy or dual therapy in real-world clinical practice.Epileptic disorders : international epilepsy journal with videotape · 2026Observational
- Perspectives on the burden of drug-resistant epilepsy and treatment priorities: Findings from a multistakeholder survey.Epilepsia open · 2026Article
- Initial Monotherapy and Further Anti-seizure Medication Regimens in Adult Patients with Epilepsy: A Population-Based, Longitudinal, Retrospective Analysis of German Prescription Data.Neurology and therapy · 2026Article
- The Burden of Epilepsy in Thailand: Estimating Societal Costs and Quality of Life.Behavioural neurology · 2026Article
- Sleep quality and its correlates in people with epilepsy: A multicenter cross-sectional study in Germany.Epilepsia · 2025Article
- Seizures beget more than seizures: Understanding the cellular, structural, individual and societal impact of seizures in epilepsy.Epilepsia open · 2025Review
- Diagnosis, treatment, and outcome prediction of non-convulsive status epilepticus in unconscious patients in intensive care units.Neurological research and practice · 2025Review
- Trends and cost structure of drug-based secondary prevention of ischemic strokes.Neurological research and practice · 2025Article
- A multicenter, matched case-control analysis comparing burden of illness among patients with tuberous sclerosis complex related epilepsy, generalized idiopathic epilepsy, and focal epilepsy in Germany.Neurological research and practice · 2024Article
- Clinical and economic implications of epilepsy management across treatment lines in Spain: a real-life database analysis.Journal of neurology · 2023Article
- Determinants of quality of life in adults with epilepsy: a multicenter, cross-sectional study from Germany.Neurological research and practice · 2023Article
- Adverse Event Profiles of Antiseizure Medications and the Impact of Coadministration on Drug Tolerability in Adults with Epilepsy.CNS drugs · 2023Article
- Impact of COVID-19 pandemic on physical and mental health status and care of adults with epilepsy in Germany.Neurological research and practice · 2022Article
- Burden of illness in people with medically refractory epilepsy who suffer from daily to weekly seizures: 12-month follow-up of participants in the EPISODE study.Frontiers in neurology · 2022Article
- Silent refractoriness in epilepsy care: cross-sectoral analysis of prescribing patterns, referrals and workforce capacity in Saxony.Frontiers in neurologyArticle
- Money Matters: Measuring the Economic Impact of Epilepsy.Epilepsy currentsArticle
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study was undertaken to quantify epilepsy-related costs of illness (COI) in Germany and identify cost-driving factors.
methodsCOI were calculated among adults with epilepsy of different etiologies and severities. Multiple regression analysis was applied to determine any epilepsy-related and sociodemographic factors that serve as cost-driving factors.
resultsIn total, 486 patients were included, with a mean age of 40.5 ± 15.5 years (range = 18-83 years, 58.2% women). Mean 3-month COI were estimated at €4911, €2782, and €2598 for focal, genetic generalized, and unclassified epilepsy, respectively. The mean COI for patients with drug-refractory epilepsy (DRE; €7850) were higher than those for patients with non-DRE (€4720), patients with occasional seizures (€3596), or patients with seizures in remission for >1 year (€2409). Identified cost-driving factors for total COI included relevant disability (unstandardized regression coefficient b = €2218), poorer education (b = €2114), living alone (b = €2612), DRE (b = €1831), and frequent seizures (b = €2385). Younger age groups of 18-24 years (b = -€2945) and 25-34 years (b = -€1418) were found to have lower overall expenditures. A relevant disability (b = €441), DRE (b = €1253), frequent seizures (b = €735), and the need for specialized daycare (b = €749) were associated with higher direct COI, and poorer education (b = €1969), living alone (b = €2612), the presence of a relevant disability (b = €1809), DRE (b = €1831), and frequent seizures (b = €2385) were associated with higher indirect COI. SIGNIFICANCE: This analysis provides up-to-date COI data for use in further health economics analyses, highlighting the high economic impacts associated with disease severity, disability, and disease-related loss of productivity among adult patients with epilepsy. The identified cost drivers could be used as therapeutic and socioeconomic targets for future cost-containment strategies.
Indexed as
Identifiers
35192210What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.